On October 6th, Dr. Sonia Ziesche, Principal and Patent Agent at Gowling WLG will join Wendy Hurlburt, President and CEO at Life Sciences BC to discuss the IP journey of a life sciences company from research to commercialization. They will cover different types of IP protection, patent requirements and obstacles, IP best practices in the field of life sciences as well as tips on how to align IP strategy to advance business goals.
Click Here for event details.
The faculty of medicine’s Dr. Steven Miller and Dr. Fabio Rossi are among 102 new Fellows elected to the Royal Society of Canada (RSC) in recognition of their outstanding scholarly and scientific achievement.
Join us virtually on Monday September 12th for the Faculty of Medicine Translational Medicine’s monthly Rounds.
For information and registration about the event, Click Here
Registration for the Clinical Trials BC Investigator Training Program 2022 (Hybrid Event) is now open.
Clinical Trials BC and Pfizer are partnering to bring a clinical trial investigator training course to British Columbia this November 2, 2022. Completion of this course satisfies Good Clinical Practice training requirements and TransCelerate mutual recognition criteria for conducting clinical trials.
Date and Time: –
Event Organization: Clinical Trials BC
Location: Virtual or at Jack Poole Hall, Robert H. Lee Alumni Centre, UBC, Vancouver
UBC Faculty of Medicine’s Drs. Karim Khan, Kathleen Martin Ginis, and Julio Montaner (pictured) are among 71 new Fellows elected into the Canadian Academy of Health Sciences (CAHS) for 2022. Election to Fellowship in the CAHS is considered one of the highest honours for individuals in the Canadian health sciences community.
A newly identified link between chronic pain and lung cancer in a pre-clinical model offers hope for pain management
Pain is an important alarm system engineered to provoke rapid withdrawal from harmful situations.
But for hundreds of millions of people, the alarm bells keep going off long after healing from an initial injury. Persistent pain may arise in the absence of stimulus, injury, or disease. Despite its prevalence, chronic pain is among the least well-managed and least understood areas of healthcare.
The Canadian National Proteomics Network (CNPN) has named Dr. Leonard Foster (UBC Biochemistry and Molecular Biology and Michael Smith Labs) as its 2022 recipient of the Tony Pawson Proteomics Award. Kristensen Mol BioSys 2013
Presented today at the CNPN annual meeting, held in Montreal from May 16-18th, 2022, the award recognized Dr. Foster’s lifetime contributions to the developments of proteomics technologies.
One of the key technologies was the basis for a significant publication in Cell last year, entitled “An atlas of protein-protein interactions across mouse tissues.” The July 2021 study opened up new avenues to uncover regulatory mechanisms that shape interactome responses to normal and abnormal stimuli in mammalian systems. Work described in the paper relied on techniques for characterizing protein interactions and protein complexes on a system-wide scale, particularly co-migration and measurement of large-scale temporal changes to protein interaction networks: A cutting edge proteomics method first described by Foster and colleagues in 2012.
Click Here for the original article.
We are very pleased to announce the successful completion of the inaugural ATM Visiting Scientist Program with Dr. Stefan Burdach. Dr. Burdach was visiting from March to June of 2022 from the Translational Pediatric Cancer Research Action, Institute of Pathology and Children’s Cancer Research Center, Department of Pediatrics at Technical University of Munich School of Medicine and was hosted at the BC Cancer Research Institute.
Dr. Burdach’s scientific merits include four decades of bringing together basic science and clinical application in the field of pediatric oncology and hematology and significant accomplishments in establishing a research collaboration across the Atlantic Ocean to fight childhood cancer, in particular the main cause of death in these diseases, metastasis. Dr. Burdach’s work has not only elucidated important mechanisms of metastatic spread but has also developed targeted immunotherapies to potentially target the metastatic process.
We look forward to continuing the work and partnership with Dr. Burdach and his colleagues to help advance translational medicine at the University of British Columbia.
The ATM Visiting Professorship program aims to forge further collaborations between the University of British Columbia Faculty of Medicine and other translational medicine centres of excellence across the world.
